Incannex is a clinical stage pharmaceutical development company that is
developing unique medicinal cannabinoid pharmaceutical products and psychedelic
medicine therapies for the treatment of anxiety disorders, obstructive sleep
apnoea (OSA), traumatic brain injury (TBI)/concussion, lung inflammation (ARDS,
COPD, asthma, bronchitis), rheumatoid arthritis and inflammatory bowel disease.
U.S. FDA approval and registration, subject to ongoing clinical success, is
being pursued for each drug and therapy under development. Each indication
represents major global markets and currently have no, or limited, existing
registered pharmacotherapy (drug) treatments available to the public.
